617 related articles for article (PubMed ID: 25582496)
21. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
[TBL] [Abstract][Full Text] [Related]
22. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A
Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403
[TBL] [Abstract][Full Text] [Related]
24. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.
Katsuya Y; Fujita Y; Horinouchi H; Ohe Y; Watanabe S; Tsuta K
Lung Cancer; 2015 May; 88(2):154-9. PubMed ID: 25799277
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 Status in Refractory Lymphomas.
Vranic S; Ghosh N; Kimbrough J; Bilalovic N; Bender R; Arguello D; Veloso Y; Dizdarevic A; Gatalica Z
PLoS One; 2016; 11(11):e0166266. PubMed ID: 27861596
[TBL] [Abstract][Full Text] [Related]
27. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 expression in neuroendocrine tumors of the lung.
Tsuruoka K; Horinouchi H; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Asakura K; Nakagawa K; Sakurai H; Watanabe SI; Tsuta K; Ohe Y
Lung Cancer; 2017 Jun; 108():115-120. PubMed ID: 28625622
[TBL] [Abstract][Full Text] [Related]
29. Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation.
von Hardenberg J; Hartmann S; Nitschke K; Worst TS; Ting S; Reis H; Nuhn P; Weis CA; Erben P
Clin Genitourin Cancer; 2019 Apr; 17(2):145-153.e5. PubMed ID: 30709785
[TBL] [Abstract][Full Text] [Related]
30. Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine Tumours.
Pinato DJ; Vallipuram A; Evans JS; Wong C; Zhang H; Brown M; Dina RE; Trivedi P; Akarca AU; Marafioti T; Mauri FA; Sharma R
Neuroendocrinology; 2021; 111(5):465-474. PubMed ID: 32097935
[TBL] [Abstract][Full Text] [Related]
31. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
Hirai M; Kitahara H; Kobayashi Y; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
Int J Oncol; 2017 Jan; 50(1):41-48. PubMed ID: 27922697
[TBL] [Abstract][Full Text] [Related]
32. Expression of PD-L1 Identifies a Subgroup of More Aggressive Non-Small Cell Carcinomas of the Lung.
Sterlacci W; Fiegl M; Droeser RA; Tzankov A
Pathobiology; 2016; 83(5):267-75. PubMed ID: 27225345
[TBL] [Abstract][Full Text] [Related]
33. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.
Sheng J; Fang W; Yu J; Chen N; Zhan J; Ma Y; Yang Y; Huang Y; Zhao H; Zhang L
Sci Rep; 2016 Jan; 6():20090. PubMed ID: 26822379
[TBL] [Abstract][Full Text] [Related]
34. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
[TBL] [Abstract][Full Text] [Related]
35. Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.
Xu J; Sun HH; Fletcher CD; Hornick JL; Morgan EA; Freeman GJ; Hodi FS; Pinkus GS; Rodig SJ
Am J Surg Pathol; 2016 Apr; 40(4):443-53. PubMed ID: 26752545
[TBL] [Abstract][Full Text] [Related]
36. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
Merelli B; Massi D; Cattaneo L; Mandalà M
Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
[TBL] [Abstract][Full Text] [Related]
37. siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions.
Iwamura K; Kato T; Miyahara Y; Naota H; Mineno J; Ikeda H; Shiku H
Gene Ther; 2012 Oct; 19(10):959-66. PubMed ID: 22113316
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
[TBL] [Abstract][Full Text] [Related]
39. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
[TBL] [Abstract][Full Text] [Related]
40. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.
Droeser RA; Hirt C; Viehl CT; Frey DM; Nebiker C; Huber X; Zlobec I; Eppenberger-Castori S; Tzankov A; Rosso R; Zuber M; Muraro MG; Amicarella F; Cremonesi E; Heberer M; Iezzi G; Lugli A; Terracciano L; Sconocchia G; Oertli D; Spagnoli GC; Tornillo L
Eur J Cancer; 2013 Jun; 49(9):2233-42. PubMed ID: 23478000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
